Cardiol Therapeutics Inc. Class A Common Shares (CRDL)
Stock · NASDAQ · Health Care
$1.1as of 10/16/2026
Price chart
Active signals
CRDL Signal Track Record
How signals performed across all stocks →What CRDL's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 44 | -2.9% | 41% | October 2, 2026 |
| Bollinger Band Breakout | 28 | -4.9% | 39% | August 10, 2026 |
| Bollinger Band Breakdown | 16 | +7.0% | 75% | October 2, 2026 |
| 200-Day Moving Average TouchActive now | 12 | +0.9% | 50% | October 8, 2026 |
| Any 20-session window (baseline) | 0.0% | 49% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CRDL
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of rec…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 18
- Website
- www.cardiolrx.com/
Fundamentals
- 1-day range
- $1.09$1.14
- Market cap
- $156.77M
- P/E (trailing)
- —
- P/E (forward)
- -4.78
- EPS (trailing)
- $-0.34
- Dividend yield
- —
- Beta
- 2.79
- Avg. volume
- 1.42M
Forecasts
5 analyst ratings
Cardiol Therapeutics Inc. Class A Common Shares Competitors
Chosen by industry and closest market cap.
- CRDLCardiol Therapeutics Inc. Class A Common Shares$1.1▼ 4.35%Market cap $156.77MP/E —$1.23$3.23
- TNYATenaya Therapeutics Inc. Common Stock$0.381▼ 6.62%Market cap $157.50MP/E —$0.3601$2.04
- HUMAHumacyte Inc. Common Stock$0.429▼ 2.50%Market cap $157.54MP/E —$0.337$1.9
- CRBUCaribou Biosciences Inc. Common Stock$0.47▲ 1.08%Market cap $162.66MP/E —$0.4425$3.54
- MOLNMolecular Partners AG American Depositary Shares$3.56▼ 2.47%Market cap $163.47MP/E —$2.66$3.96
- LENZLENZ Therapeutics Inc. Common Stock$3.27▼ 8.40%Market cap $163.67MP/E —$3.35$42.98
- ABOSAcumen Pharmaceuticals Inc. Common Stock$1.69▲ 1.20%Market cap $164.68MP/E —$1.5$3.6
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CRDL Cardiol Therapeutics Inc. Class A Common Shares | $156.77M | — | $1.1 | ▼ 4.35% | $1.23$3.23 |
| TNYA Tenaya Therapeutics Inc. Common Stock | $157.50M | — | $0.381 | ▼ 6.62% | $0.3601$2.04 |
| HUMA Humacyte Inc. Common Stock | $157.54M | — | $0.429 | ▼ 2.50% | $0.337$1.9 |
| CRBU Caribou Biosciences Inc. Common Stock | $162.66M | — | $0.47 | ▲ 1.08% | $0.4425$3.54 |
| MOLN Molecular Partners AG American Depositary Shares | $163.47M | — | $3.56 | ▼ 2.47% | $2.66$3.96 |
| LENZ LENZ Therapeutics Inc. Common Stock | $163.67M | — | $3.27 | ▼ 8.40% | $3.35$42.98 |
| ABOS Acumen Pharmaceuticals Inc. Common Stock | $164.68M | — | $1.69 | ▲ 1.20% | $1.5$3.6 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- HC Wainwright & Co. Reiterates Buy on Cardiol Therapeutics, Maintains $9 Price TargetBenzinga · 9/23/2026
- Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s EfficacyYahoo · 9/23/2026
- Cardiol Therapeutics Announces Enrollment Progress And Plans To Expand Its MAVERIC Phase III Trial Evaluating CardiolRx For Risk Reduction Of Recurrence In Patients With Recurrent PericarditisBenzinga · 9/23/2026
- Cardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in ProceedsYahoo · 9/16/2026
- 5 Small Drug Stocks Poised to Benefit From a Biotech RecoveryYahoo · 9/14/2026
- Cardiol Therapeutics: Q1 2027 Readout Will Be Make-Or-Break For MavericSeekingAlpha · 9/12/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 27.84M
- Total value held
- $37.54M
- Institutional holders
- 45
- Unknown15.35M
- Unknown5.13M
- Unknown2.73M
- Unknown896.5K
- Unknown794.9K
- Unknown534.2K
- Unknown465.0K
- Unknown332.4K
- Unknown250.4K
- Unknown229.8K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Cardiol Therapeutics Advances Phase III Trial, Positive Outlook
Cardiol Therapeutics reported it reached its Phase III MAVERIC enrollment target earlier than expected and has added more patients to the trial to better evaluate CardiolRx’s effectiveness. The company also plans to expand the trial to assess the drug’s ability to reduce recurrence in patients with recurrent pericarditis. Analysts continue to view the company positively, keeping a $9 price target. The news supports the company’s growth narrative and may influence market perception.
Cardiol Therapeutics Advances Phase III Trial, Positive Outlook. Cardiol Therapeutics reported it reached its Phase III MAVERIC enrollment target earlier than expected and has added more patients to the trial to better evaluate CardiolRx’s effectiveness. The company also plans to expand the trial to assess the drug’s ability to reduce recurrence in patients with recurrent pericarditis. Analysts continue to view the company positively, keeping a $9 price target. The news supports the company’s growth narrative and may influence market perception.